HCW Biologics Inc (nasdaq:HCWB) Share Price

Company Profile

Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact
2929 N Commerce Parkway
MiramarFL33025
USA
T: +1 954 842-2024
https://www.hcwbiologics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,061.20	20.50	-0.23%
CAC 40	7,905.83	51.22	0.65%
DAX 40	23,696.96	22.43	0.09%
Dow JONES (US)	46,142.42	124.10	0.27%
FTSE 100	9,225.38	2.73	-0.03%
HKSE	26,545.10	0.25	0.00%
NASDAQ	22,470.72	209.40	0.94%
Nikkei 225	45,045.81	257.62	-0.57%
NZX 50 Index	13,231.66	111.63	0.85%
S&P 500	6,631.96	31.61	0.48%
S&P/ASX 200	8,773.50	18.70	-0.21%
SSE Composite Index	3,820.09	11.57	-0.30%